At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 5, 2026 at 08:30 ET
Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63.5M from $34.1M a year ago on higher R&D and SG&A costs. The key catalyst is the completed enrollment of the Phase 3 APOLLO trial for bitopertin in EPP, with topline data expected in Q4 2026, which could support an FDA resubmission by mid-2027.
- Q1 2026 EPS of -$1.65 vs consensus -$1.73 (4.6% beat)
- Net loss widened to $63.5M from $34.1M YoY, driven by higher R&D ($45.9M vs $27.8M) and SG&A ($23.6M vs $12.2M)
- Cash, cash equivalents, and marketable securities of $730.2M, providing runway into 2029
- Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (183 patients); topline data expected Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access